Anthera Pharmaceuticals is a biopharmaceutical company focused on developing and commercializing products to treat autoimmune diseases. Co. has one Phase 3 ready product candidate, blisibimod, which targets elevated levels of B-cell activating factor (BAFF), which has been associated with a range of B-cell mediated autoimmune diseases, including systemic lupus erythematosus, Immunoglobin A nephropathy, lupus nephritis, vasculitis, rheumatoid arthritis, idiopathic thrombocytopenia purpura, and others. Blisibimod (also referred to as A-623) is a peptibody antagonist of the BAFF cytokine.
Nothing in The Online Investor is intended to be investment advice, nor does it represent the opinion of, counsel
from, or recommendations by BNK Invest Inc. or any of its affiliates, subsidiaries or partners.
None of the information contained herein constitutes a recommendation that any particular security, portfolio,
transaction, or investment strategy is suitable for any specific person. All viewers agree that under no
circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held
liable for any loss or damage caused by your reliance on information obtained. By visiting, using or viewing this site, you
agree to the following Full Disclaimer & Terms of Service. Video widget and stock market videos powered by Market News Video. Quote data delayed at least 20
minutes, powered by Ticker Technologies, and Mergent. Contact The Online Investor; Meet Our Editorial Staff.